Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Dec;11(6):876-878.
doi: 10.21037/hbsn-22-432.

Atezolizumab plus bevacizumab for patients with Child-Pugh-B in hepatocellular carcinoma

Shinji Itoh  1 , Masafumi Ikeda  2
Affiliations
Editorial

Atezolizumab plus bevacizumab for patients with Child-Pugh-B in hepatocellular carcinoma

Shinji Itoh et al. Hepatobiliary Surg Nutr. 2022 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-22-432/coif). MI reports lecture/ honoraria for Bayer, Chugai, Eisai, Eli Lilly Japan, Takeda; receiving grant from Bristol Myers Squibb, MSD, Chugai, Bayer, Eisai, Eli Lilly Japan, and Takeda. The other author has no conflicts of interest to declare.

Comment on

References

    1. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 2020;382:1894-905. 10.1056/NEJMoa1915745 - DOI - PubMed
    1. Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 2022;76:862-73. 10.1016/j.jhep.2021.11.030 - DOI - PubMed
    1. D'Alessio A, Fulgenzi CAM, Nishida N, et al. Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study. Hepatology 2022;76:1000-12. 10.1002/hep.32468 - DOI - PMC - PubMed
    1. Marrero JA, Kudo M, Venook AP, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study. J Hepatol 2016;65:1140-7. 10.1016/j.jhep.2016.07.020 - DOI - PubMed
    1. Kudo M, Matilla A, Santoro A, et al. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. J Hepatol 2021;75:600-9. 10.1016/j.jhep.2021.04.047 - DOI - PubMed

LinkOut - more resources